Why Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies In Anaphylm Application – And What's Next [Yahoo! Finance]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
epinephrine sublingual film, which may delay potential approval beyond the current January 31, 2026 action date. At the same time, the company is pressing ahead with global plans for Anaphylm, preparing regulatory submissions in Canada, Europe, and the UK based on a broad clinical program that showed a pharmacokinetic profile comparable to leading epinephrine auto-injectors and generally similar safety to epinephrine. We'll now examine how this fresh FDA feedback on Anaphylm's application reshapes Aquestive's investment narrative built around a first-in-class oral epinephrine launch. Uncover the next big thing with financially sound penny stocks that balance risk and reward To own Aquestive Therapeutics today, you have to believe that Anaphylm can still reach the market as a first oral epinephrine option despite fresh regulatory uncertainty. The FDA's unspecified deficiencies directly affect the main near term catalyst and heighten the biggest current risk: further delay or fa
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Jim Cramer: The whole Aquestive situation seems very ambiguous [CNBC]CNBC
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQSTPR Newswire
- INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQSTGlobeNewswire
- Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle [Seeking Alpha]Seeking Alpha
AQST
Earnings
- 11/5/25 - Miss
AQST
Sec Filings
- 1/9/26 - Form 8-K
- 12/5/25 - Form 4
- 12/4/25 - Form 4
- AQST's page on the SEC website